Biohaven Reports Q1 Non-GAAP EPS ($1.64), Consensus ($1.47)
Biohaven | 10-Q: Quarterly report
Earnings Flash (BHVN) BIOHAVEN LTD. Reports Q1 Loss $-1.64 Per Share, Vs. FactSet Est of $-1.70
Biohaven | 8-K: Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
Express News | Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
Express News | Biohaven Q1 Operating Expenses USD 221.561 Million
Press Release: Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
Biohaven 1Q Loss/Shr $2.17 >BHVN
Biohaven Ltd. Shareholders Approve Key Proposals at Meeting
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
UBS Adjusts Biohaven Price Target to $40 From $65, Maintains Buy Rating
Biohaven Secures $600m Financing as It Awaits FDA Prodrug Decision
Baird Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $57
Why BioHaven Stock Is Soaring Today
$BHVN Stock Is up 7% Today. Here's What We See in Our Data.
Sector Update: Health Care Stocks Mixed Premarket Monday
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Baird Maintains Outperform on Biohaven, Lowers Price Target to $57
Biohaven Analyst Ratings